Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients
who are having excessive drooling.
The primary goal of the study is to determine if the patient perceives a benefit from the
Myobloc in controlling excessive drooling.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborators:
ALS Association Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System University of Kansas
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA rimabotulinumtoxinB